In which countries is cemiplimab available?

Cemiplimab (Cemiplimab) is a fully human monoclonal antibody that targets programmed death receptor-1 (PD-1). It enhances the anti-tumor activity of T cells by blocking the PD-1 pathway, thereby improving the body's immune response to a variety of solid tumors.

Cimepilimab was initially approved by the U.S. Food and Drug Administration (FDA) in September 2018 for the treatment of advanced or metastatic cutaneous squamous cell carcinoma (CSCC), becoming the first immunotherapy approved by the FDA for this indication. Since then, the indications for cimepilimab have gradually expanded to include some patients with advanced basal cell carcinoma (BCC) and some patients with non-small cell lung cancer (NSCLC), especially cases with positive PD-L1 expression.

In the European market, cimepilimab was approved by the European Commission in June 2019, under the trade name Libtayo, for the treatment of locally advanced or metastatic CSCC, as well as some patients with advanced non-small cell lung cancer. The launch in Europe enables more patients to obtain cimepilimab treatment through formal channels and promotes the application of immunotherapy in the management of skin cancer and lung cancer. In addition to the United States and the European Union, cimepilimab has also been approved for marketing in Canada, Australia, Japan and other countries. These countries have evaluated the safety and effectiveness of the drug through strict regulatory procedures.

It is worth noting that the original drug of cimepilimab has not yet received marketing approval in mainland China. Although it has been widely used in overseas markets, domestic patients still need to obtain the drug through clinical trials or special drug import policies. Overseas marketing experience shows that cimepilimab has stable efficacy and can significantly delay disease progression and improve quality of life in patients with advanced skin cancer and some lung cancer. With the accumulation of international clinical data and the advancement of regulatory review, cimepilimab is expected to enter the markets of more countries, including China, in the future, providing new immunotherapy options for more patients.

Reference materials:https://www.libtayohcp.com/